Literature DB >> 17991358

Treatment considerations in advanced endometrial cancer.

James E Kendrick1, Warner K Huh.   

Abstract

An estimated 39,080 new cases of endometrial cancer will occur in the United States in 2007, along with 7400 deaths associated with this disease. Fortunately, with surgical staging, the majority of women are diagnosed with disease at an early stage and are often completely treated with a hysterectomy alone. However, 13% of women who are surgically staged have stage III disease, and 3% to 13% have stage IV disease identified at that time. Over the past 10 years, the role of cytoreductive surgery, radiotherapy, and chemotherapy in endometrial cancer have been actively investigated. This review outlines and summarizes some of these important developments and findings.

Entities:  

Mesh:

Year:  2007        PMID: 17991358     DOI: 10.1007/s11912-007-0069-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  16 in total

1.  The role of surgical cytoreduction in Stage IV endometrial carcinoma.

Authors:  D S Chi; M Welshinger; E S Venkatraman; R R Barakat
Journal:  Gynecol Oncol       Date:  1997-10       Impact factor: 5.482

2.  Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.

Authors:  R E Bristow; M J Zerbe; N B Rosenshein; F C Grumbine; F J Montz
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

3.  Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.

Authors:  G F Fleming; J M Fowler; S E Waggoner; L J Copeland; B E Greer; I Horowitz; G Sutton; R J Schilder; P M Fracasso; H G Ball; W P McGuire
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

4.  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.

Authors:  H G Ball; J A Blessing; S S Lentz; D G Mutch
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

5.  Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

Authors:  J T Thigpen; J A Blessing; H Homesley; W T Creasman; G Sutton
Journal:  Gynecol Oncol       Date:  1989-04       Impact factor: 5.482

6.  Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  C J Cohen; H W Bruckner; G Deppe; J A Blessing; H Homesley; J H Lee; W Watring
Journal:  Obstet Gynecol       Date:  1984-05       Impact factor: 7.661

7.  Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  G F Fleming; V L Filiaci; R C Bentley; T Herzog; J Sorosky; L Vaccarello; H Gallion
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

8.  Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  J T Thigpen; H J Buchsbaum; C Mangan; J A Blessing
Journal:  Cancer Treat Rep       Date:  1979-01

9.  Surgical stage IV endometrial carcinoma: a study of 47 cases.

Authors:  B A Goff; A Goodman; H G Muntz; A F Fuller; N Nikrui; L W Rice
Journal:  Gynecol Oncol       Date:  1994-02       Impact factor: 5.482

10.  A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.

Authors:  J T Thigpen; J A Blessing; P J DiSaia; E Yordan; L F Carson; C Evers
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

View more
  1 in total

1.  Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.

Authors:  Yanzhen Lin; Wei Wang; Junkai Wan; Ying Yang; Wenkun Fu; Dequan Pan; Linli Cai; Tong Cheng; Xiumin Huang; Yifeng Wang
Journal:  Virol J       Date:  2018-04-10       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.